Operator

Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma conference call. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes.

It is now my pleasure to hand the conference call over to Ashlee Dunston, aTyr's Senior Director of Investor Relations and Public Affairs. Ms. Dunston, you may begin.

Ashlee Dunston
Director of Investor Relations & Corporate Communications

Thank you, and good afternoon, everyone. Thank you for joining us today to discuss a regulatory and clinical update for our efzofitimod in pulmonary sarcoidosis program.

Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and aTyr guests and responses to questions on this conference call are forward-looking statements under the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.

Please see the forward-looking statement disclaimer in the company's press release issued this afternoon as well as the risk factors in the company's SEC filings and included in our most recent annual report